Company intelligence / Profile preview

ASIT Biotech

Liège, Liège, Belgiumlive.euronext.com ↗

Ownership: Private
Employees: ~26
Development stage: Phase 3

Overview

The Phase III trial for gp-ASIT+™ was reported to be on track with positive momentum. The company has internalized clinical batch production capabilities demonstrating full integration from manufacturing to clinical development. The treatment aims at improved safety profile and shorter treatment duration compared to existing allergy immunotherapies[3][6].

Therapeutic areas: Immunology
Modalities: Allergy immunotherapy products based on a proprietary peptide technology platform (ASIT+™), consisting of highly purified natural allergen fragments/peptides.
Industry: Biotech

Drug pipeline

3 assets

gp-ASIT+

Phase 3

Indications: Grass pollen rhinitis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ASIT Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASIT Biotech.

Explore the full profile